What Is Enterocin? Definition and What Research Reports

Definition

Enterocin is a collective term for antimicrobial peptides — a subclass of molecules called bacteriocins — that are produced and secreted by bacteria of the genus Enterococcus, most commonly Enterococcus faecium and Enterococcus faecalis. Bacteriocins are ribosomally synthesised peptides that a bacterium releases to inhibit or kill competing bacteria in the same ecological niche. Because dozens of structurally distinct enterocins have been isolated from different strains, the word is rarely used alone in the literature: individual peptides carry an identifier such as enterocin DD14, enterocin LD3, enterocin CHQS, enterocin C or enterocin 12a. Confusingly, the name "enterocin" is also used for an unrelated bacterial polyketide natural product whose chemical total synthesis has been described separately (PMID 34278701); that molecule is a small organic compound, not a peptide, and the two share only a name.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing here describes human use, and enterocins are not marketed as therapeutic drugs.

What Class of Molecule It Is

Most enterocins fall into the class II bacteriocins — small, heat-stable, unmodified or minimally modified peptides, typically fewer than 60 amino acids. Sub-categories that appear in the literature include:

• Class IIa (pediocin-like): peptides with a conserved N-terminal motif, frequently described as anti-Listeria.
• Class IIb (two-peptide): systems requiring two complementary peptides for full activity; enterocin DD14 was characterised as a leaderless two-peptide bacteriocin (PMID 28104423).
• Leaderless bacteriocins: peptides synthesised without an N-terminal leader sequence, again exemplified by enterocin DD14 (PMID 39304058).

Enterocins are therefore peptides in the strict biochemical sense — chains of amino acids — which is why they appear in peptide reference material. They are not research peptides of the metabolic or growth-factor type; their described context is microbiology, food preservation and antimicrobial discovery.

Where It Comes From

Enterocins are isolated from enterococcal strains recovered from a wide range of natural sources. Researchers characterised enterocin LD3 from Enterococcus hirae LD3 (PMID 27145777), and other reports described bacteriocinogenic E. faecium and E. faecalis isolated from human milk alongside screening of their virulence traits (PMID 29238458). Enterocin-producing Enterococcus strains have also been isolated from sheep and goat colostrum and put through a formal safety assessment (PMID 39375633). Production is a fermentation problem as much as a chemistry one: one study applied a Taguchi experimental design to optimise enterocin production from a probiotic E. faecium strain (PMID 38994812). Chemical synthesis has also been reported — the two peptides of enterocin DD14 were produced synthetically in a study that then examined their antimicrobial activity and mechanism (PMID 39304058).

How the Term Is Used in Peptide Research

In the published literature, "enterocin" is used in four recurring ways:

1. As a named peptide under mechanistic study — for example, work describing enterocin C targeting the undecaprenyl phosphate recycling protein BacA (PMID 41232670).
2. As a food-preservation agent — antilisterial enterocins were characterised and then applied to a model fresh cheese (PMID 28703625).
3. As a probiotic trait — the ability to produce enterocins is one criterion used when screening Enterococcus isolates, and it is generally assessed alongside virulence and antibiotic-resistance markers (PMID 29238458).
4. As an antimicrobial-discovery scaffold — enterocins are examined for activity beyond bacteria, including against yeast, as in the analysis of enterocin CHQS mechanisms against Candida albicans (PMID 35552837).

What the Published Literature Reports

The evidence base is preclinical and largely in vitro. Researchers reported that enterocin DD14 was a leaderless two-peptide bacteriocin with activity against Clostridium perfringens, and that study described it as safe in the assays performed (PMID 28104423). A separate study reported anti-adhesion and anti-inflammatory potential for the same class IIb leaderless bacteriocin in cell-based models (PMID 35604525). A synthetic version of enterocin DD14 was characterised for antimicrobial activity with accompanying mechanistic studies (PMID 39304058). Work on enterocin LD3 reported biochemical properties and a proposed mechanism of action after purification from E. hirae LD3 (PMID 27145777), while enterocin 12a from E. faecium was reported to have both antimicrobial and anticancer potential in laboratory assays (PMID 33541292). Antifungal activity was described for enterocin CHQS against Candida albicans, with the authors investigating the underlying antimicrobial mechanisms (PMID 35552837). More recent structural work reported that enterocin C acts on BacA, a protein involved in undecaprenyl phosphate recycling in the bacterial cell-wall pathway (PMID 41232670).

Safety and Tolerability: What Studies Report

No human dosing trials of enterocins appear in the verified literature summarised here, so no dose, route or duration can be stated. Safety discussion in this field centres on the producing organism rather than the peptide alone, because Enterococcus species can carry virulence and antibiotic-resistance determinants. A safety assessment of enterocin-producing Enterococcus strains isolated from sheep and goat colostrum evaluated those characteristics directly (PMID 39375633), and a separate study screened bacteriocinogenic E. faecium and E. faecalis from human milk for virulence traits alongside their bacteriocin production (PMID 29238458). The enterocin DD14 report described the peptide as safe within the assays that study performed (PMID 28104423). These are laboratory characterisations, not clinical safety data.

Related Terms

• Bacteriocin — the broader class of ribosomally synthesised antimicrobial peptides produced by bacteria; enterocins are the enterococcal members.
• Nisin — a lantibiotic bacteriocin from Lactococcus, often discussed alongside enterocins in food-preservation contexts.
• Leaderless bacteriocin — a peptide produced without a cleavable N-terminal leader sequence (PMID 39304058).
• Biopreservation — the use of microbial metabolites to control spoilage or pathogenic organisms in food, as with antilisterial enterocins applied to model fresh cheese (PMID 28703625).

References

• Biomimetic Total Synthesis of Enterocin (Angewandte Chemie International ed. in English, 2021)
• Antimicrobial Mechanisms of Enterocin CHQS Against Candida albicans (Current Microbiology, 2022)
• Biochemical Properties and Mechanism of Action of Enterocin LD3 Purified from Enterococcus hirae LD3 (Probiotics and Antimicrobial Proteins, 2016)
• Synthesis, antimicrobial activity, and mechanistic studies of enterocin DD14, a leaderless two-peptide bacteriocin (International Journal of Biological Macromolecules, 2024)
• Anticancer and antimicrobial potential of enterocin 12a from Enterococcus faecium (BMC Microbiology, 2021)
• Characterization and Application of Antilisterial Enterocins on Model Fresh Cheese (Journal of Food Protection, 2017)
• Mechanistic insights into enterocin C targeting the undecaprenyl phosphate recycling protein BacA (Journal of Biological Chemistry, 2026)
• Optimization of Enterocin Production from Probiotic Enterococcus faecium Using Taguchi Experimental Design (Turkish Journal of Pharmaceutical Sciences, 2024)
• Anti-adhesion and Anti-inflammatory Potential of the Leaderless Class IIb Bacteriocin Enterocin DD14 (Probiotics and Antimicrobial Proteins, 2022)
• The safe enterocin DD14 is a leaderless two-peptide bacteriocin with anti-Clostridium perfringens activity (International Journal of Antimicrobial Agents, 2017)
• Bacteriocinogenic potential and virulence traits of Enterococcus faecium and E. faecalis isolated from human milk (Iranian Journal of Microbiology, 2017)
• Safety assessment of enterocin-producing Enterococcus strains isolated from sheep and goat colostrum (BMC Microbiology, 2024)